TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02327975

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Training group
Description: The main part of the session included a whole-body strength training, which incorporated chest press, shoulder press, lateral pull-down, seated row, shoulder flexion, chest pulley, hammer curl, biceps curl, triceps curl, triceps pushdown, leg extension, leg curl, lunge, squat, abdominal crunch. To control and equate the intensity between the TG and MG, a method based on the combined use of the prescribed number of repetitions and the OMNI Resistance Scale for the active muscles was used. Previous studies have described the method used for controlling exercise intensity (Colado et al., 2012; Colado et al., 2014).~During 1-3 weeks subjects performed 25 min of exercise at 60% maximum heart rate (HRmax), during weeks 4-6 subjects performed 30 min of exercise at 70% HRmax and during weeks 7-10 subjects performed 35 min of exercise at 80% HRmax.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mobile group
Description: The subjects in this group received the same intervention that trainning group but through a mobile application (whatsapp).
Study: NCT00233948

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: immunoenzyme technique
Description: Correlative studies
Study: NCT01838850

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CS8635 20/5/12.5mg and placebo
Description: Run-in period: Coated, Oral tablet containing Olmesartan medoxomil(OM)-Hydrochlorothiazide(HCTZ) 20-12.5mg, given once a day.~Double-blind period: Coated, Oral tablet containing Olmesartan medoxomil(OM)-Amlodipine (AML)-Hydrochlorothiazide(HCTZ) 20-5-12.5mg, oral placebo tablet. All tablets are given once a day.~Open-label period: Coated, Oral tablet containing Olmesartan medoxomil(OM)-Amlodipine(AML)-Hydrochlorothiazide(HCTZ) 40-5-12.5mg, given once a day.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Olmetec® Plus 20/12.5mg and placebo
Description: Run-in period: Coated, Oral tablet containing Olmesartan medoxomil(OM)-Hydrochlorothiazide(HCTZ) 20-12.5mg, given once a day.~Double-blind period: Coated, Oral tablet containing Olmesartan medoxomil(OM)-Hydrochlorothiazide(HCTZ) 20-12.5mg, oral placebo tablet. All tablets are given once a day.~Open-label period: Coated, Oral tablet containing Olmesartan medoxomil(OM)-Amlodipine(AML)-Hydrochlorothiazide(HCTZ) 20-5-12.5mg, given once a day.
Study: NCT00550459

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tolvaptan
Description: 15-60 mg oral tablet given once a day for 21 days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablet given once daily for 21 days
Study: NCT02543944

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gabapentin
Description: N-type calcium channel blocker being examined for its potential efficacy to alleviate opioid withdrawal during buprenorphine-assisted detoxification and transition to depot naltrexone.
Study: NCT02327975

Intervention type: OTHER
Group type: OTHER
Intervention: Control group
Description: No received intervention.
Study: NCT03189550

Intervention type: PROCEDURE
Intervention: ERAS perioperative care
Description: Standard of care implementation of multi-modal evidence-based care pathway, including standardized preoperative preparation (medical and diet), perioperative goal-directed fluid therapy, multi-modal perioperative pain management, postoperative nausea and vomiting prevention, surgical care and bowel isolation, and surgical site infection prevention

Intervention type: PROCEDURE
Intervention: ERAS perioperative care
Description: Standard of care implementation of multi-modal evidence-based care pathway, including standardized preoperative preparation (medical and diet), perioperative goal-directed fluid therapy, multi-modal perioperative pain management, postoperative nausea and vomiting prevention, surgical care and bowel isolation, and surgical site infection prevention

Intervention type: PROCEDURE
Intervention: Standard perioperative care
Description: Standard perioperative care prior to implementation of ERAS care pathway

Intervention type: PROCEDURE
Intervention: Standard perioperative care
Description: Standard perioperative care prior to implementation of ERAS care pathway

Intervention type: PROCEDURE
Intervention: Standard perioperative care
Description: Standard perioperative care prior to implementation of ERAS care pathway

Intervention type: PROCEDURE
Intervention: Noninvasive hemodynamic monitoring
Description: Standard of care perioperative noninvasive hemodynamic monitoring with the ClearSight System (Edwards LifeSciences)
Study: NCT02301299

Intervention type: BEHAVIORAL
Intervention: Community-based Stroke Awareness Program
Description: A culturally-adapted stroke awareness and action program will be delivered by trained Stroke Promoters in the targeted neighborhoods in the south side of Chicago. Community Stroke Promoters will be trained on 1) the benefits of early recognition and EMS utilization for stroke (i.e. stroke centers, tPA), 2) culturally-adapted solutions to current barriers (i.e. misperceptions about vulnerability, severity, mistrust, costs), and 3) cues to aid in stroke recognition and immediate action. The intervention will take place at community settings throughout a 1-year period.
Study: NCT01245998

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dalteparin
Description: dalteparin 5000 I.U./24 h s.c. for 6 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dalteparin
Description: dalteparin 15000 I.U./24 h s.c. for 6 weeks
Study: NCT00119366

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: total-body irradiation
Description: Undergo TBI

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: allogeneic hematopoietic stem cell transplantation
Description: Undergo PBSC transplantation

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: allogeneic hematopoietic stem cell transplantation
Description: Undergo PBSC transplantation

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: allogeneic hematopoietic stem cell transplantation
Description: Undergo PBSC transplantation

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: allogeneic hematopoietic stem cell transplantation
Description: Undergo PBSC transplantation

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: allogeneic hematopoietic stem cell transplantation
Description: Undergo PBSC transplantation

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: peripheral blood stem cell transplantation
Description: Undergo PBSC transplantation

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: peripheral blood stem cell transplantation
Description: Undergo PBSC transplantation

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: peripheral blood stem cell transplantation
Description: Undergo PBSC transplantation

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: peripheral blood stem cell transplantation
Description: Undergo PBSC transplantation

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: peripheral blood stem cell transplantation
Description: Undergo PBSC transplantation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclosporine
Description: Given IV or PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclosporine
Description: Given IV or PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclosporine
Description: Given IV or PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclosporine
Description: Given IV or PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclosporine
Description: Given IV or PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mycophenolate mofetil
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mycophenolate mofetil
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mycophenolate mofetil
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mycophenolate mofetil
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mycophenolate mofetil
Description: Given PO
Study: NCT02543944

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Buprenorphine
Description: All participants are stabilized on buprenorphine and then undergo a 10 day taper off buprenorphine.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Buprenorphine
Description: All participants are stabilized on buprenorphine and then undergo a 10 day taper off buprenorphine.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clonidine
Description: All participants who successfully taper off buprenorphine receive Clonidine (0.1 mg) prior to induction onto oral naltrexone.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Clonidine
Description: All participants who successfully taper off buprenorphine receive Clonidine (0.1 mg) prior to induction onto oral naltrexone.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Naltrexone (oral)
Description: All participants receive increasing doses of oral naltrexone over a 3 day period (day 1: 6.25 and 6.25 mg; day 2: 25 mg; day 3: 50 mg)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Naltrexone (oral)
Description: All participants receive increasing doses of oral naltrexone over a 3 day period (day 1: 6.25 and 6.25 mg; day 2: 25 mg; day 3: 50 mg)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Naltrexone (depot)
Description: All participants who tolerate oral naltrexone at 50 mg will receive the naltrexone injection on either the same day as the 50 mg dose or the day after.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Naltrexone (depot)
Description: All participants who tolerate oral naltrexone at 50 mg will receive the naltrexone injection on either the same day as the 50 mg dose or the day after.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Microcrystalline cellulose
Study: NCT00119366

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT01193179

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OPC-262
Description: Oral administration of tablets for 52 weeks
Study: NCT02864355

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Goal Directed Therapy
Description: Participants in this group will have a FloTrac monitor attached to their arterial line and the Goal Directed Therapy algorithm will be followed to manage blood pressures.
Study: NCT02325076

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Spirodoc
Description: A device to detect the physical condition of the lungs
Study: NCT01073085

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Web-based automated coaching by e-mails
Study: NCT00119366

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT04492111

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: post-extraction dental implant
Description: Insertion of a dental implant immediately after tooth extraction.
Study: NCT01073085

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Self-help guide
Study: NCT03771287

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Oticon OpenSound Navigator speech enhancement algorithm
Description: OpenSound Navigator (OSN) is a speech enhancement algorithm developed by Oticon. The feature is built in Oticon's current OPN™ hearing aid platform and can be adjusted and disabled in the programming. It is designed to automatically enhance speech while reducing unwanted background noise to improve communication for the user.
Study: NCT04492111

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: post-extraction dental implant
Description: Insertion of a dental implant immediately after tooth extraction.
Study: NCT00654979

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SafeFlo IVC Filter
Description: SafeFlo IVC Filter
Study: NCT00306059

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Early goal directed therapy during 6 hours after occurence of the early phase of acute kidney injury
Description: Directed therapy during 6 hours after occurence of the early phase of acute kidney injury.
Study: NCT02754258

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MPH
Description: 60 days on oral methylphenidate administered 2 times daily before lunch and supper.
Study: NCT02507635

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levocetirizine
Description: administration of Levocetirizine 5 mg/day for 4 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Desloratadine
Description: administration of Desloratadine 5 mg/day for 4 weeks
Study: NCT03771287

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Oticon omni-directional microphone algorithm
Description: Omni-directional microphone setups come standard for all Oticon hearing aid models. The hearing microphones have equal sensitivity across all directions.
Study: NCT02088697

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ASC-01
Study: NCT02688738

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxycycline
Study: NCT01564303

Intervention type: DRUG
Group type: NO_INTERVENTION
Intervention: Acetylcysteine, Phosphodiesterase type 5 inhibitor ,Carnitine
Description: to evaluate the effect of the above agents on Kidney functioning parameters

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetylcysteine, Phosphodiesterase type 5 inhibitor ,Carnitine
Description: to evaluate the effect of the above agents on Kidney functioning parameters

Intervention type: DRUG
Group type: NO_INTERVENTION
Intervention: Acetylcysteine, Phosphodiesterase type 5 inhibitor ,Carnitine
Description: to evaluate the effect of the above agents on Kidney functioning parameters

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetylcysteine, Phosphodiesterase type 5 inhibitor ,Carnitine
Description: to evaluate the effect of the above agents on Kidney functioning parameters
Study: NCT03098511

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Neurological Diagnostic Evaluation
Description: Clinical Data:~* Demographic data~* Daily data (clinical exams, laboratory data)~* Drug administration~* Additional clinical or ancillary neurological determination test~Diagnostic Intervention:~* CT-Perfusion~* CT-Angiography reconstructions~Reference Standard:~- Clinical Neurological Exam~Blood Samples (Pharmacokinetics, Inflammatory \& Nanovesicles Parameters):~* At the time of patient enrolment~* 6 hours after patient enrolment~* At the time of the clinical neurological exam~Secondary Outcome measures at 6 months:~* extended Glasgow Outcome Scale (GOSe)~* modified Rankin Scale (mRS)
Study: NCT02754258

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 60 days on oral placebo administered 2 times daily before lunch and supper
Study: NCT03833466

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: metformin and chemotherapy
Description: Drug: Metformin Metformin is orally administered as 500mg bid for 7 days and escaladed to 500mg tid if adverse events are tolerated.~Drug: Cisplatin Cisplatin is given at 75mg/m2 intravenously on day 1 of each 21 day cycle.~Drug: Paclitaxel Paclitaxel is given at 175mg/m2 intravenously on day 1 of each 21 day cycle.
Study: NCT02567565

Intervention type: OTHER
Intervention: LipiView
Description: tear film lipid layer thickness measured by LipiView interferometer (TearScience Inc, Morrisville, NC)
Study: NCT00510744

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pancreatic enzyme supplement
Description: 4 caps with meals, 2 with snacks
Study: NCT01719133

Intervention type: DRUG
Group type: OTHER
Intervention: placebo
Description: saline solution
Study: NCT01910818

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fractional CO2 laser treatment
Description: Patient will be treated with fractional laser treatment over the areas with fibrosis.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: No treatment
Description: Patient will also have an area that is not being treated with CO2 laser. This is the area not getting treatment.
Study: NCT00524420

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: rTMS
Description: 10 Hz, 4-second trains, 26-second intertrain interval, 75 trains/session, 15 sessions at 120% motor threshold rTMS to left dorsolateral prefrontal cortex

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham rTMS
Description: 10 Hz, 4-second trains, 26-second intertrain interval, 75 trains/session, 15 sessions of sham rTMS
Study: NCT03474874

Intervention type: DEVICE
Group type: OTHER
Intervention: NeoMatriX Collagen Dressing
Description: Collagen wound dressing
Study: NCT03498456

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tegoprazan/Amoxicillin/Clarithromycin
Description: Tegoprazan 50 mg + Amoxicillin 1000 mg + Clarithromycin 500 mg bid. This therapy will be administered for a total of 7 days, in fasting conditions in the morning and the evening.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lansoprazole/Amoxicillin/Clarithromycin
Description: Lansoprazole 30 mg + Amoxicillin 1000 mg + Clarithromycin 500 mg bid. This therapy will be administered for a total of 7 days, in fasting conditions in the morning and the evening.
Study: NCT01697982

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Living with Hope Program
Description: The Living with Hope Program involves viewing a short film entitled Living with Hope, which is based on the research team's grounded theory study, and shows cases of terminally ill persons and their family members talking about how they maintain their hope. Participants then choose to begin one of three hope activities: a) Write or ask someone to help you write one or more letters to someone begin to write a letter to someone, b) Begin a Hope Collection or c) begin an About Me Collection.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: LWH film
Description: Participants will view the Living with Hope film which is based on the research team's grounded theory study, and shows cases of terminally ill persons and their family members talking about how they maintain their hope.
Study: NCT02169089

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Spironolactone
Description: Patients will be given Spironolactone 12.5 mg on week 0 (visit 2). Patients will be escalated to 25 mg daily Spironolactone or maximal tolerated dose over a 4-week period. Patients will continue treatment for an additional 48 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT01714947

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [^14C]-alisertib
Description: \[\^14C\]-alisertib oral solution
Study: NCT03222856

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: MK3475 (pembrolizumab) will be supplied directly as a solution for infusion in a single-use vial. Each vial contains 100 mg of MK3475 (pembrolizumab) in 4 ml of solution.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eribulin
Description: Eribulin will be supplied as a clear and colourless aqueous solution for injection provided in glass vials containing 2 ml. Each 2 ml vial contains eribulin mesylate equivalent to 0.88 mg eribulin.
Study: NCT02368483

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neuromuscular training
Description: Neuromuscular training for the hip and lower limb muscles.The training program is divided into 3 phases, and includes specific exercises for improving the hip range of motion, muscle strength of the hip and lower limb muscles, as well as the trunk stability and coordination. The intervention lasts 12 weeks. Patients will train 2 times/week with a physical therapist and 2 times/weeks alone at home.
Study: NCT01719133

Intervention type: DRUG
Group type: OTHER
Intervention: Histamine
Description: positive control

Intervention type: DRUG
Group type: OTHER
Intervention: AllerT1
Description: synthetic peptide T1

Intervention type: DRUG
Group type: OTHER
Intervention: AllerT2
Description: synthetic peptide T2

Intervention type: DRUG
Group type: OTHER
Intervention: AllerT3
Description: synthetic peptide T3

Intervention type: DRUG
Group type: OTHER
Intervention: AllerT4
Description: synthetic peptide T4
Study: NCT01714947

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: alisertib
Description: Alisertib enteric coated tablets
Study: NCT00677742

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: enhanced initial supply of oral contraception
Description: 7 packs of pills, or 1 pack of pills and a prescription for 6 refills
Study: NCT01719133

Intervention type: DRUG
Group type: OTHER
Intervention: AllerT5
Description: synthetic peptide T5

Intervention type: DRUG
Group type: OTHER
Intervention: mix of AllerT1-T2-T3
Description: mix of peptides T1, T2 and T3

Intervention type: DRUG
Group type: OTHER
Intervention: mix of AllerT4-T5
Description: mix T4-T5
Study: NCT02815592

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986012

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986012

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986012

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Study: NCT00677742

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: conventional initial supply of oral contraception
Description: 3 packs of pills, or 1 pack of pills and a prescription for 2 refills
Study: NCT02815592

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Etoposide
Study: NCT02477215

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MLN9708
Description: 4 mg of MLN9708 delivered on days 1, 8 and 15 of a 28 day cycle.
Study: NCT02815592

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Study: NCT02815592

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Platinum

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Platinum

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Study: NCT01438450

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral
Description: Capecitabine : 500 mg OD x 1 week 500 mg BD x 1 week 500 mg (2 morning, 1 evening) x 1 week After attaining the max dose of 1500 mg, a cycle of Capecitabine 1500mg every day for 2 weeks and 1 week off to be maintained.~Thalidomide: 50 mg OD x 1 week 100 mg OD x 1 week 200 mg OD x 1 week, 300 mg OD x 1 week

Intervention type: OTHER
Group type: NO_INTERVENTION
Intervention: Supportive
Description: No specific therapy will be given